AcelRx Pharma (ACRX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ACRX Hot Sheet
Join SI Premium – FREE
AcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of ($0.25), $0.02 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.89 million.
For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real Industry (RELY) Tops Q3 EPS by 15c; offers guidance
- Crane NXT, Co. (CXT) Tops Q3 EPS by 8c
- Power Integrations (POWI) Tops Q3 EPS by 5c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
